Articles from Parker Institute for Cancer Immunotherapy

As the global oncology community gathers for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30–June 3), the Parker Institute for Cancer Immunotherapy (PICI) is demonstrating how bold science, accelerated through collaborative networks, can drive meaningful progress where patients need it most. At a pivotal moment when scientific breakthroughs in immunotherapy are arriving alongside heightened pressure for faster, smarter impact, PICI's integrated model shows how to compress timelines from discovery to patient care.

The Parker Institute for Cancer Immunotherapy (PICI), a collaborative consortium of the world’s leading immuno-oncology experts that bridges scientific discovery and commercialization of cancer therapies, today announced the appointment of Ira Mellman, PhD, as President of Research. Dr. Mellman’s extensive expertise in cancer immunology and cell biology will be instrumental in advancing PICI's mission to transform innovative research into curative treatments for patients worldwide.

The Parker Institute for Cancer Immunotherapy (PICI), a collaborative consortium of the world’s leading immuno-oncology experts, today announced its inaugural 2024 class of Representation in SciencE (RISE) Scholar award recipients. Selected through PICI's Diversity, Equity, Inclusion and Belonging (DEIB) Program, these seven outstanding researchers are pursuing innovative immunotherapy projects that could transform cancer treatment.

​Powered by a commitment to accelerating bold, emerging science, the Parker Institute for Cancer Immunotherapy (PICI) continues to invest in the next generation of scientific leaders and their ambitious ideas for curative cancer treatments.

The Parker Institute for Cancer Immunotherapy (PICI) is helping to forge a future without cancer, by investing in today’s top talent to train and empower the research leaders of tomorrow. This year, PICI recognized its largest Early Career Researcher class yet, nine exceptional graduate and postdoctoral researchers from leading academic institutions. They will share a total of up to $4.5 million in fellowship and scholarship awards.

Researchers have identified certain patients with pancreatic cancer who may be more likely to benefit from combination treatment regimens consisting of immunotherapy and chemotherapy. These new data, stemming from a long-term collaboration between academia, biotech, pharma and nonprofits within the Parker Institute for Cancer Immunotherapy (PICI) network, were shared with the medical community at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago today. The comprehensive clinical and immunologic findings of the Phase II clinical trial, known as the PRINCE study, were published simultaneously in the peer-reviewed journal Nature Medicine.